CBPB

(redirected from Calcium-Based Phosphate Binder)
AcronymDefinition
CBPBCoded Block Pattern for B-Type Macroblock
CBPBComparative Biochemistry and Physiology-Part B (course)
CBPBCement Bonded Particle Board
CBPBCalcium-Based Phosphate Binder (kidney metabolism)
CBPBClassic Biphasic Pulmonary Blastoma
CBPBContinuous Brachial Plexus Blockade (pain management)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
A combination of calcium-based phosphate binder, sevelamer, lanthanum carbonate hydrate, calcitriol, alfacalcidol, maxacalcitol, and cinacalcet was titrated according to the serum calcium, phosphate, or PTH levels.
Treatment of aluminum bone disease Avoid antiresorptive agents such as bisphosphonates and denosumab Avoid PTH oversuppression due to calcimimetics or excessive use of the active form of vitamin D Avoid high calcium dialysate Avoid excessive calcium-based phosphate binder Consider using the following: noncalcium, nonaluminum-based phosphate binders; native vitamin D to achieve calcidiol levels of 20-30 ng/mL; low calcium dialysate (1.25 mmol/L); recombinant PTH and antisclerostin monoclonal antibodies 5.2.2.
There are several calcium-based phosphate binder products on the market, such as calcium acetate, calcium carbonate, and calcium citrate, which come in a variety of formulations.
Review calcium-based phosphate binders and calcitriol supplementation dosing, or initiate this therapy if hypocalcaemic.
* Avoid calcium-based phosphate binders in patients with known vascular calcifications.
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.
Studies in the dialysis population also report that sevelamer use results in less hypercalcemia, attenuation of arterial calcification, lower incidence of coronary artery calcification, decreased mortality, and reduced hospitalization compared to calcium-based phosphate binders (Block et al., 2005; Block, Raggi, Bellasi, Kooienga, & Spiegel, 2007; Chertow, Burke, & Raggi, 2002; Suki et al., 2007).
The three- year trial involving more than 2,100 patients compared the difference in mortality and morbidity outcomes for patients receiving Renagel (sevelamer hydrochloride) with those using calcium-based phosphate binders. Renagel is a polymer that binds excess phosphorous in the blood.
ATLANTA -- Calcium-based phosphate binders, which are widely used to manage hyperphosphatemia in dialysis patients, appear to be an important contributor to the extraordinarily high rate of cardiovascular mortality that is seen in this population.
Calcium-based phosphate binders emerged as alternatives to aluminum salts.
Calcium-based phosphate binders and/or vitamin D analogues should be limited if patients experience hypercalcemia, arterial calcification, adynamic bone disease and/or if the serum PTH levels become persistently low (KDIGO, 2009; National Kidney Foundation, 2003).
The association between CUA and higher Ca x P and serum phosphorus levels, as well as the use of 1,25 OH vitamin D sterols plus calcium-based phosphate binders, suggests that control of modifiable factors may allow clinicians to prevent CUA in some patients (Fine & Zacharias, 2002).
Full browser ?